🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Today marks the celebration of Family Day in Israel, a day that recognizes the diverse dynamics, roles and structures of family units and celebrates the differences that make each one special. Happy Family Day! #FamilyDay #IsraelFamilyDay

Two poster presentations highlighted Gamida Cell research at #Tandem24, hosted by ASTCT & CIBMTR. Learn more in our press release: investors.gamida-cell.com/news-releases/… #celltherapy #ASTCT #CIBMTR

Mark your calendars! See what’s new with Gamida at this year’s NMDP One Forum and ASTCT Toxicities Conference.

We’re excited to welcome APHEXDA® (motixafortide) into the Gamida Cell portfolio, strengthening our commitment to innovative therapies. Together with OMISIRGE® (omidubicel-onlv), we’re advancing options for patients in need of stem cell transplants. #GamidaCell #APHEXDA

Looking forward to the ASH Annual Meeting? #ASH24 Join us on December 8, 8-9am PT as Dr. Ronit Simantov presents “Options When a Matched Allo-HSCT is Not Available”. WARNING: INFUSION REACTIONS, GRAFT VERSUS HOST DISEASE, ENGRAFTMENT SYNDROME, and GRAFT FAILURE. See Full

Our team is arriving in San Diego! Visit our booths (2247 + 2346) at #ASH24 to learn more about Omisirge® (omidubicel-onlv). WARNING: INFUSION REACTIONS, GRAFT VERSUS HOST DISEASE, ENGRAFTMENT SYNDROME, and GRAFT FAILURE. See full Prescribing Information, including Boxed

Aloha! We're excited to be in Hawaii for #Tandem25! Stop by Gamida Cell Booth 101 to chat with our team and discover the benefits of Omisirge® (omidubicel-onlv). WARNING: INFUSION REACTIONS, GRAFT VERSUS HOST DISEASE, ENGRAFTMENT SYNDROME, and GRAFT FAILURE. See full Prescribing

Exploring treatment options in allo-HSCT? Join us on February 12, 1:30-2:30pm HST in PIT Room 3 as Dr. Stephanie Tsai and Dr. Ronit Simantov present “Options When a Matched Allo-HSCT is Not Available”. #Tandem25 WARNING: INFUSION REACTIONS, GRAFT VERSUS HOST DISEASE,

RoslinCT has entered into a strategic partnership with Gamida Cell to manufacture their FDA-Approved Cell Therapy Omisirge®, a commercial product for the treatment of hematologic malignancies. Read the full press release here: hubs.la/Q03bgG7H0